Business
Sun Pharmaceutical Industries Limited Press Release Jul 21 2025
Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release, titled Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint.
About this update from Sun Pharmaceutical Industries Limited
[{"type":"text","content":" Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release, titled Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint. View Attachment","length":371,"tagName":"div"}]